Tofapredict-study (Immunology in psoriatic arthritis)

Tofapredict is a clinical trial in which 200 PsA patiënts will be included and treated with MTX, Tofacitinib, Etanercept or a combination of these. The aim is to investigate epigenome, transcriptome, metabolome and proteome with the systems medicine approach. Hereby we try to identify molecular pathways that contribute to the pathogenesis of the disease and to identify biomarkers that predict which patients will react to each specific medicine (personalized medicine).

Contact 
Nienke Kleinrensink & Frank Perton